GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Revolution Medicines
Revolution Medicines is a biotech company developing innovative drugs for targeted cancer therapy. Its stock price is driven by news from its clinical trials. The chart reflects investor confidence in the potential of its scientific platform for creating new drugs.
Share prices of companies in the market segment - Cancer cure
Revolution Medicines operates in the biotechnology sector, developing targeted drugs for cancer treatment. We classify it as part of the Cancer Treatment sector. The chart below reflects the dynamics of this entire innovative, yet risky, pharmaceutical segment.
Broad Market Index - GURU.Markets
Revolution Medicines is an oncology company developing targeted therapies that target hard-to-reach cancer-causing proteins, particularly those in the RAS family. Its innovativeness has earned it a spot in the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
RVMD - Daily change in the company's share price Revolution Medicines
Revolution Medicines, a biotech company, is highly volatile due to its reliance on research results. Daily price changes directly reflect this sensitivity to news. This metric is a key element in complex formulas on System.GURU.Markets that analyze risks in the innovative medicine sector.
Daily change in the price of a set of shares in a market segment - Cancer cure
Revolution Medicines, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with RVMD's performance, which depends on the clinical trial results of its targeted drugs, helps to assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Revolution Medicines is a biopharmaceutical company developing targeted cancer therapies targeting RAS proteins. Oncology is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating Revolution Medicines stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Revolution Medicines
Revolution Medicines is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Cancer cure
Revolution Medicines, Inc. is a biotech company focused on developing innovative targeted therapies for cancers caused by RAS mutations. Its scientific approach targets difficult-to-treat tumors. The chart shows how the market views the potential of its breakthrough technology compared to the broader biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Revolution Medicines is a biotech company whose stock price is completely disconnected from economic cycles. Its share price reflects investor hopes for the success of clinical trials of new cancer drugs. The company's chart isn't about economics, but about science, risk, and the potential for breakthroughs that could change lives and generate enormous profits.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Revolution Medicines
The performance of Revolution Medicines, a biopharmaceutical company, is speculative. The monthly fluctuations on the chart reflect not business cycles, but rather investor reactions to news about the clinical trials of its innovative anti-cancer drugs, which determine the company's entire future value.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the biotech sector. For Revolution Medicines, an oncology company, it's the backdrop. Its movements demonstrate how promising early-stage data for its targeted therapies for hard-to-treat cancers generate high investor expectations, driving its valuation ahead of the broader sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Revolution Medicines is a biotech company focused on oncology. Its shares are driven by news about drug development. Their price can soar or collapse in a single day based on clinical trial data, completely ignoring the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Revolution Medicines
Revolution Medicines is a biotech company focused on targeted cancer therapy. Its weekly stock price exhibits the extreme volatility typical of biotech, driven by clinical trial data releases and FDA news.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Revolution Medicines is an oncology biotech. Comparing its weekly performance to the biotech sector can be misleading. This chart shows how news about its unique approach to cancer treatment gives the stock a life of its own, often defying broader industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Revolution Medicines, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
RVMD - Market capitalization of the company Revolution Medicines
The Revolution Medicines market capitalization chart tells the story of cutting-edge oncology research. Its dynamics reflect investor hopes for a new class of drugs targeting RAS proteins, previously considered "untouchable." Every fluctuation represents the market's reaction to clinical trial data that could revolutionize cancer treatment.
RVMD - Share of the company's market capitalization Revolution Medicines within the market segment - Cancer cure
Revolution Medicines is a biotech company focused on developing innovative targeted therapies for cancers caused by mutations in the RAS gene family. Its market share reflects high hopes for a breakthrough in this complex area of oncology. The chart below shows the weight investors place on it in the race for a cure.
Market capitalization of the market segment - Cancer cure
Revolution Medicines is a biotech company developing innovative targeted cancer therapies targeting RAS signaling pathways. The chart below shows the overall market capitalization of the oncology sector, reflecting the enormous scientific and commercial interest in new approaches to cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows the front lines of the fight against cancer. Revolution Medicines develops drugs targeting hard-to-reach oncogenes like KRAS. Its volatile market cap reflects the hopes and risks of oncology, where every research success can lead to a breakthrough in treatment and a surge in stock prices.
Book value capitalization of the company, segment and market as a whole
RVMD - Book value capitalization of the company Revolution Medicines
Revolution Medicines' book value is derived from its intellectual property in targeted cancer therapy (especially RAS inhibitors) and the capital it has to conduct clinical trials. This is the scientific foundation. The chart shows how the biotech company accumulates the resources needed to advance its innovative drugs through the complex and expensive development stages.
RVMD - Share of the company's book capitalization Revolution Medicines within the market segment - Cancer cure
Revolution Medicines is a biotech company focused on developing cancer drugs that attack hard-to-reach targets. Its assets are cutting-edge laboratories. The chart shows that its value lies in its scientific platform and intellectual property, not its manufacturing capacity.
Market segment balance sheet capitalization - Cancer cure
Revolution Medicines, a biopharmaceutical company, develops targeted cancer therapies. Its business is capital-intensive from a scientific perspective. The BCap_Seg chart for the biotech sector shows that the industry as a whole relies on expensive labs rather than large-scale manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Revolution Medicines' capital isn't its factories, but rather its cutting-edge research platform and patent portfolio for innovative cancer treatments. Its book value reflects the capital invested in research and clinical trials. The chart shows how this research-intensive asset compares to giants with manufacturing capabilities.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Revolution Medicines
Revolution Medicines' balance sheet is its scientific platform. Its entire market value is a premium on its innovative approach to cancer treatment by targeting RAS proteins, long considered "untouchable." Its valuation is a bet on a scientific breakthrough in oncology.
Market to book capitalization ratio in a market segment - Cancer cure
Revolution Medicines is a biotech company developing innovative cancer treatments. Its valuation is based almost entirely on the scientific potential of its developments. The chart reflects the high expectations investors have for its R&D platform.
Market to book capitalization ratio for the market as a whole
Revolution Medicines is a biotech company developing innovative cancer drugs targeting hard-to-reach targets. Its value is derived almost entirely from its intellectual property and the potential of its scientific platform. The chart shows how highly the market values its chances of developing breakthrough drugs.
Debts of the company, segment and market as a whole
RVMD - Company debts Revolution Medicines
Revolution Medicines, a biotech company focused on targeted cancer therapy, uses capital to fund its cutting-edge research and clinical trials. Developing innovative cancer drugs requires significant investment. This chart shows how the company raises funds to advance its scientific approach to cancer treatment.
Market segment debts - Cancer cure
Revolution Medicines is a biotech company developing innovative targeted drugs for cancer treatment. Drug development is a long, expensive, and risky process. Its leverage reflects the stage of clinical trials and confidence in the scientific platform. This chart shows how the company funds its cutting-edge research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Revolution Medicines
Revolution Medicines is a biotech company developing innovative drugs for targeted cancer therapy. This process requires significant investment in R&D. The chart shows how the company finances its expensive research. The debt level here is an indicator of financial risk before clinical trial results are available.
Market segment debt to market segment book capitalization - Cancer cure
Revolution Medicines is a biotech company developing innovative targeted drugs for the treatment of cancers caused by RAS mutations. This is a cutting-edge, but very expensive, area of research. The chart shows how the company's debt load to fund R&D compares to the market capitalization and risks of the overall oncology sector.
Debt to book value of all companies in the market
Revolution Medicines, a biotech company, is funding its own expensive cancer research. This chart allows us to assess the scale of this risky investment by comparing the company's debt to the total capitalization of the entire stock market. This places the risks of biotech in a broader economic context.
P/E of the company, segment and market as a whole
P/E - Revolution Medicines
Revolution Medicines is a clinical-stage biotech company focused on developing innovative targeted therapies for cancers caused by mutations in the RAS genes. This chart reflects investor expectations. The company's valuation is based on the potential of its scientific platform to create breakthrough drugs.
P/E of the market segment - Cancer cure
Revolution Medicines is a biotech company targeting difficult-to-treat cancers. This chart shows the average valuation for the biotech sector. It emphasizes that Revolution Medicines' valuation is based on the highest expectations for its scientific platform, not on current revenue.
P/E of the market as a whole
Revolution Medicines is a biotech company focused on developing innovative cancer treatments targeting specific mutations, such as KRAS. This chart shows the overall risk appetite in biotech. Revolution Medicines' valuation, however, depends almost entirely on the success of its scientific developments and clinical trial results.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Revolution Medicines
Revolution Medicines is a biotech company developing innovative targeted therapies for the treatment of cancers caused by RAS mutations. This chart reflects the high expectations associated with a potential breakthrough in oncology. The trendline estimates the likelihood of success in its clinical trials.
%20P%2FE%20Revolution%20Medicines&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Revolution-Medicines&v=1772634896823 "Chart of the company's future (projected) P/E Revolution Medicines")
Future (projected) P/E of the market segment - Cancer cure
Revolution Medicines is a biotech company specializing in the development of innovative targeted therapies for the treatment of cancers caused by mutations in the RAS gene family. This chart shows profitability expectations for the sector, helping to understand how highly the market values the company's scientific approach to one of the most challenging targets in oncology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772634896873 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Revolution Medicines is a clinical-stage biotech focused on developing innovative targeted therapies for cancer. This chart shows investors' risk appetite. For a company working on breakthrough but risky projects in oncology, it reflects the market's willingness to fund long-term scientific research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772634896879 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Revolution Medicines
Revolution Medicines is a clinical-stage biotechnology company focused on developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS genes. The financial metrics presented here represent investments in research. The chart illustrates the cost of developing breakthrough cancer treatments.
Profit of companies in the market segment - Cancer cure
Revolution Medicines is a clinical-stage oncology company focused on developing innovative targeted therapies that target key cancer-causing mutations, particularly the RAS gene family. This graph reflects the high potential and risk in biotechnology, where a scientific breakthrough in treating common cancers can lead to a blockbuster.
Overall market profit
Revolution Medicines is a biotechnology company developing innovative targeted cancer therapies targeting RAS proteins. Its success depends on breakthroughs in clinical trials. The company is at the forefront of science and represents a high-risk investment in the future of oncology, made possible by a strong and innovative economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Revolution Medicines
Revolution Medicines is a biotech company developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS gene family. The earnings forecast in this chart reflects analysts' expectations for clinical trial successes of its innovative cancer treatment approaches.
%20profit%20of%20the%20company%20Revolution%20Medicines&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Revolution-Medicines&v=1772634896951 "Graph of future (projected) profit of the company Revolution Medicines")
Future (predicted) profit of companies in the market segment - Cancer cure
Revolution Medicines is an oncology company developing innovative targeted therapies that target key mutations in the RAS family of genes, long considered untreatable. This chart shows the revenue forecast for the cancer treatment sector, allowing one to assess the scientific and commercial potential of Revolution Medicines' breakthrough research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772634896970 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Revolution Medicines is a biotech company developing targeted therapies for cancer treatment. Its success depends on the results of clinical trials. This chart, reflecting stock market sentiment, affects the availability of capital to fund long-term and risky research in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772634896996 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Revolution Medicines
Revolution Medicines is a biotech company developing a new class of targeted oncology drugs targeting RAS proteins. This chart reflects the high expectations of investors. The high revenue valuation (often from partnerships) is a bet on a breakthrough in treating one of the most challenging targets in cancer therapy.
P/S market segment - Cancer cure
Revolution Medicines, Inc. is a clinical-stage biotechnology company developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS gene family. This chart reflects investor expectations for companies in the sector, providing insight into how the market views Revolution Medicines' scientific potential and developments.
P/S of the market as a whole
Revolution Medicines is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancers caused by mutations in the RAS gene family. This chart helps understand how the market values biotech companies working on breakthrough but risky oncology projects relative to the overall market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Revolution Medicines
Revolution Medicines is a biotech company developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS genes. This chart shows the company's valuation relative to its future, currently projected, sales. It reflects investor hopes for a breakthrough in treating one of the most challenging targets in oncology.
%20P%2FS%20Revolution%20Medicines&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Revolution-Medicines&v=1772634897213 "The graph of the company's future (projected) P/S Revolution Medicines")
Future (projected) P/S of the market segment - Cancer cure
Revolution Medicines is an oncology company developing innovative targeted therapies that target key mutations that cause cancer, particularly the RAS protein family. The company is at the forefront of cancer research. This chart reflects the high investor expectations for its scientific platform and potential future sales.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772634897274 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Revolution Medicines is a biotech company developing innovative targeted therapies for the treatment of cancers caused by RAS mutations. Its success depends entirely on the results of clinical trials. This general expectations chart for RVMD is not a direct driver. The company's value is determined by the scientific potential of its developments, not the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772634897351 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Revolution Medicines
This graph illustrates the trajectory of an innovative oncology company. For Revolution Medicines, it reflects revenue from collaborations with partners during clinical trials. Significant growth potential stems from the successful development and commercialization of drugs targeting cancers caused by mutations in RAS genes.
Sales of companies in the market segment - Cancer cure
Revolution Medicines is a clinical-stage biotechnology company focused on developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS genes. Its success depends on the results of clinical trials. This schedule reflects the company's enormous potential and scientific progress in the field of oncology, where it is a pioneer.
Overall market sales
Revolution Medicines is a biotechnology company developing innovative targeted therapies for cancers caused by mutations in the RAS genes. Its scientific breakthroughs have the potential to transform treatment approaches for some of the most common types of cancer. The company is part of the vanguard of medical science shaping the future of healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Revolution Medicines
Revolution Medicines is a biotechnology company developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS gene family. Its future sales forecast depends on the success of its cutting-edge clinical trials. This schedule reflects high expectations for a breakthrough in the treatment of difficult-to-treat cancers.
%20sales%20of%20the%20company%20Revolution%20Medicines&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Revolution-Medicines&v=1772634897533 "Schedule of future (projected) sales of the company Revolution Medicines")
Future (projected) sales of companies in the market segment - Cancer cure
Revolution Medicines is a biotech company focused on developing innovative targeted cancer therapies that target RAS signaling pathways. The outlook for the oncology sector shows a huge demand for new treatments, reflecting the enormous potential for breakthrough therapies targeting previously inaccessible targets.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772634897666 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Revolution Medicines is a biotech company developing targeted therapies for cancer caused by mutations in the RAS genes. Its success depends entirely on the results of clinical trials. The overall economic situation, reflected in this chart, does not affect the medical need for its drugs, but it may influence the investment climate in the sector and the availability of financing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772634897714 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Revolution Medicines
Revolution Medicines, a biotech company specializing in the development of targeted therapies for cancers caused by mutations in RAS genes, demonstrates its scientific potential in this chart. Profitability depends on the success of its clinical programs and the ability to develop effective drugs for difficult-to-treat cancers.
Market segment marginality - Cancer cure
Revolution Medicines is a biotechnology company specializing in the development of innovative targeted cancer therapies targeting RAS proteins. This chart shows the average profitability in the oncology sector. The breakthrough potential of its developments in treating difficult-to-treat cancers may allow the company to achieve exceptionally high profitability in the future.
Market marginality as a whole
Revolution Medicines, Inc. is a biotechnology company focused on developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS genes. This chart shows average profitability. Against this backdrop, Revolution Medicines is a story about solving one of the most complex challenges in oncology. Its future profitability depends on success in clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Revolution Medicines
Revolution Medicines is a biotech company developing innovative targeted therapies for the treatment of cancers caused by mutations in the RAS genes. The growth of its team of scientists and clinical trial specialists, as reflected in this graph, would be a direct indicator of progress in advancing its promising candidates into clinical trials.
Share of the company's employees Revolution Medicines within the market segment - Cancer cure
Revolution Medicines is a clinical-stage biopharmaceutical company focused on developing innovative targeted cancer therapies targeting key oncogenic proteins, such as RAS. This chart illustrates its scientific potential, reflecting the percentage of leading oncologists and chemists working on this complex topic that the company attracts.
Number of employees in the market segment - Cancer cure
Revolution Medicines is a biotechnology company developing innovative targeted cancer therapies that target hard-to-reach oncogenic proteins. This chart illustrates cutting-edge oncology research. The company's growing team of scientists reflects advances in understanding cancer and the company's commitment to creating next-generation therapeutics.
Number of employees in the market as a whole
Revolution Medicines is a biotech company developing innovative targeted drugs for cancer treatment. Its success depends on scientific breakthroughs and clinical trial results. A stable economic environment, reflected in this chart, is essential for attracting the long-term investment needed to fund expensive R&D projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Revolution Medicines (RVMD)
Revolution Medicines is a biotech company developing innovative drugs targeting hard-to-reach oncogenes like KRAS. This chart illustrates the enormous value the market places on its cutting-edge science. Its high market capitalization per employee reflects investors' bet that its team can create a new generation of cancer drugs.
%20of%20the%20company%20Revolution%20Medicines%20(RVMD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Revolution-Medicines-RVMD&v=1772634898064 "Chart of market capitalization per employee (in thousands of dollars) of the company Revolution Medicines (RVMD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Revolution Medicines (RVMD) is a biotech company focused on developing targeted therapies for cancers caused by mutations in the RAS gene family, which have long been considered "druggable." This chart shows the industry average cost per employee, helping to assess how highly the market values their innovative R&D platform per scientist.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772634898087 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Revolution Medicines is a clinical-stage biotech company focused on developing innovative cancer drugs that target hard-to-reach targets. This chart shows a very high employee valuation, as its research has the potential to lead to breakthrough cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772634898126 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Revolution Medicines (RVMD)
Revolution Medicines is a biotech company focused on developing targeted therapies for cancers caused by mutations in the RAS gene family, long considered "intractable." This is cutting-edge science. This metric will reflect the R&D phase. It shows how much the company spends (or earns) per scientist in this challenging race to find a new class of cancer drugs.
%20Chart%20Revolution%20Medicines%20(RVMD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Revolution-Medicines-RVMD&v=1772634898161 "Company Profit Per Employee (in thousands of dollars) Chart Revolution Medicines (RVMD)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Revolution Medicines (RVMD) is a biotech company in R&D (oncology, RAS inhibitors). This chart shows the benchmark for "Cancer Treatment" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the company's "burning" of cash in the hopes of one or two mega-successes.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772634898222 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Revolution Medicines is a biotech company developing innovative targeted cancer drugs that target hard-to-reach oncogenes. This is cutting-edge science. This graph reflects the venture-based nature of the business: massive investments in R&D and top-notch scientists can lead to a blockbuster and phenomenal returns per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772634898254 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Revolution Medicines (RVMD)
Revolution Medicines is a biotech company developing innovative cancer treatments. At the current stage of research, this graph reflects the intensity of its R&D. If its drugs are commercialized, this figure could increase dramatically, demonstrating the enormous value created by a small team of scientists and clinicians.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Revolution-Medicines-RVMD&v=1772634898292 "Sales chart per company employee Revolution Medicines (RVMD)")
Sales per employee in the market segment - Cancer cure
Revolution Medicines is a biotech company specializing in targeted cancer therapy, specifically RAS oncogene inhibitors. This is at the cutting edge of science. While this metric may be low at the R&D stage, it reflects how effectively their research team generates revenue from partnerships while advancing their developments toward commercialization.
Sales per employee for the market as a whole
Revolution Medicines is a clinical-stage biotech company focused on developing innovative cancer treatments targeting RAS (oncogene) signaling pathways. This chart shows the revenue (if any) generated by its research staff. At this stage, this metric is not key and reflects affiliate fees rather than sales.
Short shares by company, segment and market as a whole
Shares shorted by company Revolution Medicines (RVMD)
Revolution Medicines is at the forefront of the fight against cancer, developing RAS inhibitors—one of the most challenging targets in oncology. This chart shows how many market participants are betting against their approach. Success promises a breakthrough, but the bears are betting on the extremely high risks of clinical development in this field and strong competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Revolution-Medicines-RVMD&v=1772634898423 "Short Shares Chart for the Company Revolution Medicines (RVMD)")
Shares shorted by market segment - Cancer cure
Revolution Medicines is a biotech company focused on developing targeted cancer therapies targeting oncogenes (such as RAS). This chart shows overall short positions across the biotech sector. The high short interest in the sector reflects general investor skepticism about the sector, concerns about clinical trial failures, and funding issues.
Shares shorted by the overall market
Revolution Medicines is a biotech company working on cancer drugs. It's a "high-risk/high-reward" stock. This chart shows the overall risk appetite. When market fear rises (the chart is upward), investors are the first to sell speculative biotechs that don't yet have stable profits, preferring to move into "safe" assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Revolution Medicines (RVMD)
Revolution Medicines is a clinical-stage biotech focused on oncology. Its shares are highly sensitive to trial news. This chart for RVMD can soar above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or general investor risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Revolution-Medicines-RVMD&v=1772634898464 "RSI 14 indicator chart for the company's stock Revolution Medicines (RVMD)")
RSI 14 Market Segment - Cancer cure
Revolution Medicines is a biotech company focused on developing innovative cancer treatments. They specialize in RAS inhibitors, which target some of the most difficult-to-treat tumors. This chart shows the overall momentum in the oncology biotech sector. It helps determine whether the entire segment is overheated by expectations of breakthroughs.
RSI 14 for the overall market
Revolution Medicines is a biotech company attacking hard-to-reach cancer targets. It's a "high-risk" business. Success depends not on economics but on trial results. However, this sentiment indicator is crucial: during moments of market euphoria, investors are willing to fund such "moonshots." In a panic, they are the first to flee risky biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RVMD (Revolution Medicines)
Revolution Medicines is a biotech company focused on targeted oncology. They are developing RAS(ON) inhibitors, a new class of drugs that target mutations previously considered "untreatable" for cancer treatment. This chart shows the average 12-month target from analysts. It reflects their assessment of the company's scientific breakthrough and the commercial potential of their lead drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RVMD-Revolution-Medicines&v=1772634898554 "A chart showing analyst consensus forecasts for the expected stock price. RVMD (Revolution Medicines)")
The difference between the consensus estimate and the actual stock price RVMD (Revolution Medicines)
Revolution Medicines (RVMD) is a biotech company attacking one of the most challenging targets in oncology—RAS mutations. Their inhibitors could be a breakthrough. This chart shows how much analysts believe in this breakthrough. It measures the gap between the price and the consensus target, reflecting the potential they see in their scientific pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RVMD-Revolution-Medicines&v=1772634898589 "A chart showing the difference between the consensus forecast and the actual stock price. RVMD (Revolution Medicines)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Revolution Medicines is a biotech company focused on "inaccessible" targets in oncology, specifically the development of RAS inhibitors (a key driver of many cancers). This chart shows analysts' overall expectations across the cancer treatment sector, reflecting whether experts believe a breakthrough can be achieved in this complex field.
Analysts' consensus forecast for the overall market share price
Revolution Medicines (RVMD) is a biotech company focused on previously inaccessible oncology targets (such as RAS). It's an R&D company. Market expectations, as seen on this chart, represent their risk appetite. During a downturn (pessimism), investors are reluctant to fund long-term research projects, even highly promising ones.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Revolution Medicines
Revolution Medicines is a biotech company focused on precision oncology. They develop drugs that target specific mutations (RAS family) long considered untreatable. This chart is an assessment of their complex scientific platform and reflects investor expectations for clinical data on their cancer drug candidates.
AKIMA Market Segment Index - Cancer cure
Revolution Medicines is a biotech focused on the most challenging class of oncology targets: RAS proteins (which were previously considered unassailable). This is high-risk but potentially revolutionary R&D. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does RevMed's futuristic (RAS-oncology) bet differentiate it from the average pharma company?
The AKIM Index for the overall market
Revolution Medicines is a biotech company focused on developing drugs for hard-to-reach oncology targets (RAS inhibitors). This is a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
